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OBJECTIVE—Interleukin-6 (IL-6) has a signiﬁcant impact on glu-
cose metabolism. However, the effects of IL-6 on insulin secretion
from pancreatic b-cells are controversial. Therefore, we analyzed
IL-6 effects on pancreatic b-cell functions both in vivo and in vitro.
RESEARCH DESIGN AND METHODS—First, to examine the
effects of IL-6 on in vivo insulin secretion, we expressed IL-6 in
the livers of mice using the adenoviral gene transfer system. In
addition, using both MIN-6 cells, a murine b-cell line, and pancre-
atic islets isolated from mice, we analyzed the in vitro effects of
IL-6 pretreatment on insulin secretion. Furthermore, using phar-
macological inhibitors and small interfering RNAs, we studied the
intracellular signaling pathway through which IL-6 may affect in-
sulin secretion from MIN-6 cells.
RESULTS—Hepatic IL-6 expression raised circulating IL-6 and
improved glucose tolerance due to enhancement of glucose
stimulated-insulin secretion (GSIS). In addition, in both isolated
pancreatic islets and MIN-6 cells, 24-h pretreatment with IL-6
signiﬁcantly enhanced GSIS. Furthermore, pretreatment of MIN-6
cells with phospholipase C (PLC) inhibitors with different mech-
anisms of action, U-73122 and neomycin, and knockdowns of the
IL-6 receptor and PLC-b1, but not with a protein kinase A inhibitor,
H-89, inhibited IL-6–induced enhancement of GSIS. An inositol
triphosphate (IP3) receptor antagonist, Xestospondin C, also
abrogated the GSIS enhancement induced by IL-6.
CONCLUSIONS—The results obtained from both in vivo and in
vitro experiments strongly suggest that IL-6 acts directly on
pancreatic b-cells and enhances GSIS. The PLC-IP3–dependent
pathway is likely to be involved in IL-6-mediated enhancements
of GSIS. Diabetes 60:537–547, 2011
I
nterleukin-6 (IL-6) is a pleiotropic cytokine produced
by several cell types, such as immune cells, adipo-
cytes, myocytes, and endothelial cells. Although IL-6
was initially identiﬁed as an immuno-modulatory
cytokine secreted from macrophages, several previous
studies revealed that IL-6 also has signiﬁcant impacts on
nonimmune events (1), including glucose metabolism.
Obesity is reportedly associated with elevation of circu-
lating IL-6 (2). Functions of IL-6 in insulin-sensitive tissues
have been explored by many researchers. There is growing
evidence suggesting that IL-6 exacerbates insulin resistance
in the liver and adipose tissue, while improving insulin
sensitivity in muscle (2). In contrast, the effect of IL-6 on
insulin secretion from pancreatic b-cells remains unclear.
The IL-6 receptor (IL-6R) was reportedly expressed in mu-
rine pancreatic b-cells (3), suggesting a direct impact of IL-6
on pancreatic b-cells. However, a number of controversial
in vitro studies demonstrated IL-6 to increase (4,5), de-
crease (6–8), and have no effect on (9) insulin secretion
from isolated pancreatic islets or b-cell lines.
On the other hand, two studies have recently suggested
stimulatory effects of IL-6 on insulin secretion in vivo. IL-6
overexpression in muscle, using an electro-transfer method,
reduced body fat with liver inﬂammation and decreased
insulin sensitivity in muscle (10). Blood glucose was also
shown to be lowered especially in fed states due to en-
hanced glucose-stimulated insulin secretion (GSIS) in mice,
although this study was focused mainly on the liver and
muscle (10). In addition, involvement of IL-6 in insulin se-
cretion was recently reported using IL-6-deﬁcient mice (3).
High fat (HF)-fed IL-6-knockout (KO) mice displayed no
pancreatic a-cell expansion and decreased glucagon levels
with impaired GSIS (3). Although the effects of IL-6 on
pancreatic a-cell expansion were mainly analyzed, the
aforementioned ﬁnding prompted us to hypothesize that
HF-induced hyperIL-6-emia enhances GSIS. Furthermore, in
human subjects as well, association of the plasma IL-6
concentration with ﬁrst-phase insulin secretion was reported
(11). Collectively, chronic elevation of plasma IL-6 concen-
trations might promote insulin secretion independently of
insulin resistance. Therefore, in the current study, to de-
termine the precise role of IL-6 in pancreatic b-cell func-
tion, we performed in vivo and in vitro experiments. We
ﬁrst expressed IL-6 in the livers of mice using the adeno-
viral gene transfer system. Hepatic IL-6 expression raised
circulating IL-6 levels accompanied by marked enhance-
ments of GSIS. We also examined the in vitro effects of
IL-6 pretreatment on insulin secretion from both pancre-
atic islets isolated from mice and MIN-6 cells, a murine
b-cell line. These experiments showed GSIS enhancement.
Finally, we demonstrated that the phospholipase C (PLC)-
inositol triphosphate (IP3) dependent pathway is involved
in IL-6 enhancement of GSIS in pancreatic b-cells.
RESEARCH DESIGN AND METHODS
Recombinant adenoviruses. Murine IL-6 cDNA was cloned from aliver cDNA
library by PCR and ligated into adenovirus vector and then transfected into 293
human embryonic kidney cells. LacZ adenovirus was used as the control (12).
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ORIGINAL ARTICLEAnimals. Animal studies were conducted in accordance with Tohoku Uni-
versity institutional guidelines. We used 8-week-old C57Bl/6N male mice,
purchased from Kyudo (Kumamoto, Japan), for in vivo gene transfer study.
Mice were housed in an air-conditioned environment, with a 12-h light-dark
cycle (light on at 09:00 A.M.), and fed a regular unrestricted diet.
Glucose, insulin, and pyruvate tolerance tests. Glucose tolerance tests
(GTT) were performed on fasted (10 h, daytime) mice. Mice were given glucose
(2 g/kg of body wt) intraperitoneally, followed by measurement of blood
glucose level (13). Insulin tolerance tests (ITT) were performed on ad libitum-
fed mice. Mice were intraperitoneally injected with human regular insulin
(0.25 units/kg of body wt; Eli Lilly, Kobe, Japan), followed by measurement of
blood glucose level (14). Pyruvate tolerance tests were performed on fasted
(10 h, daytime) mice. Mice were intraperitoneally injected with sodium py-
ruvate (2 g/kg of body wt; SIGMA, St. Louis, MO) dissolved in PBS, followed by
measurement of blood glucose levels.
Blood analysis. Blood samples were obtainedfrom fasted(10 h, daytime) mice.
Blood glucose was assayed with Antsense-III (Horiba Industry, Kyoto, Japan).
ELISA kits were used to measure plasma insulin, leptin (Morinaga, Tokyo,
Japan),IL-6(eBioscience,SanDiego,CA),adiponectin(OhtsukaPharamaceutical,
Tokyo, Japan), tumor necrosis factor-a (TNF-a) (R&D Systems, Minneapolis,
MN), and glucagon (Wako Pure Chemical, Osaka, Japan) levels. Plasma free
fatty acid (FFA) levels were determined with an NEFA C (Wako Pure Chemical,
Osaka, Japan) kit. Plasma transaminase levels were determined with a Trans-
aminase C II-test (Wako Pure Chemical, Osaka, Japan) kit.
Immunoblotting. Liver samples obtained from fasted (10 h, daytime) mice
were prepared, and tissue protein extracts (250 mg total protein) were boiled in
Laemmli buffer containing 10 mmol/L dithiothreitol, subjected to SDS-poly-
acrylamide gel electrophoresis (15). Antibody to IL-6 (MAB406, R&D Systems)
was commercially obtained.
Pancreatic insulin content. Pancreata were suspended in cold acid ethanol
(1.5% HCl in 75% ethanol) and minced with scissors, and left at 220°C for 48 h,
with sonication every 24 h (16). Insulin contents in the acid ethanol super-
natant were determined with an ELISA kit (Morinaga).
Hepatic triglyceride content. Frozen livers were homogenized, and triglyc-
erides were extracted with CHCl3:CH3OH (2:1, vol:vol), dried, and resuspended
in 2-propanol (14). Triglyceride contents were measured using a Lipidos liquid
kit (TOYOBO, Osaka, Japan).
Oxygen consumption. Oxygen consumption was measured with an O2/CO2
metabolism measuring system (model MK-5000RQ; Muromachikikai, Tokyo,
Japan). Each mouse was kept unrestrained in a sealed chamber with an air-
ﬂow of 0.5 L/min for 24 h at 25°C. Air was sampled every 3 min, and oxygen
consumptions were calculated.
Cell culture. The insulin-secreting b-cell line MIN-6 was maintained in Dul-
becco’s Modiﬁed Eagle Medium containing 25 mM glucose supplemented with
10% fetal calf serum.
Studies with isolated islets and MIN-6 cells. Pancreatic islets were isolated
from 8-week-old C57Bl/6N male mice by retrograde injection of collagenase
(Sigma) into the pancreatic duct according to the standard procedure as de-
scribed previously (16). Isolated islets were maintained in RPMI1640 medium
containing 11.1 mmol/L glucose. For insulin secretion studies, batches of 10
islets or MIN-6 cells were cultured in the medium under several conditions and
then washed with modiﬁed Krebs–Ringer bicarbonate buffer (KRBB). After
a 30-min preincubation in KRBB containing 1.67 mmol/L glucose, islets or cells
were treated for 60 min in KRBB supplemented with either 1.67 or 16.7 mmol/L
glucose. Insulin contents of isolated islets or MIN-6 cells were measured after
acid ethanol extraction. Recombinant murine IL-6 (PeproTech, London, U.K.),
U-73343, U-73122, neomycin (Sigma), Xestospongin C (Biomol, Plymouth
Meeting, PA), and H-89 (Millipore, Billerica, MA) were commercially obtained.
Histological analysis. The liver, adipose tissue, and pancreas from LacZ- and
IL-6 mice were ﬁxed with 10% formalin, embedded in parafﬁn, and sectioned.
Sections were stained with hematoxylin and eosin. For measurement of b-cell
areas, consecutive parafﬁn sections 500 mm apart spanning the entire pan-
creas (excised on 14 days after adenoviral treatments) were stained for insulin
and with hematoxylin and eosin. After staining, b-cell areas were measured in
all sections with Scion Image software (Scion Corporation, Frederick, MD) as
described previously (17).
Evaluation of gene expression by RT-PCR. Total RNAs were isolated from
50 mg of hepatic tissue from 10 h-fasted mice on day 5 after adenoviral ad-
ministration. cDNAs synthesized from 1.0 mg of total RNAs with a First Strand
cDNA Synthesis Kit (Roche, Indianapolis, IN) as described previously (18)
were evaluated with a real-time PCR quantitative system (Light Cycler Quick
System 350S; Roche Diagnostics, Mannheim, Germany), with the oligonu-
cleotides presented in Supplementary Table 1.
The relative amount of mRNA was calculated with b-actin mRNA as the
invariant control.
Small interfering RNA transfection. All small interfering RNA (siRNA)
oligonucleotides (ON-TARGETplus SMART pool) were purchased from
Thermo Fisher Scientiﬁc (MA). MIN-6 cells were transfected with siRNAs using
DhamaFECT 1 Transfection Reagent (Thermo Fisher Scientiﬁc).
Statistical analysis. All data were expressed as means 6 SE. For experiments
in which data differences needed to be assessed among three or more groups,
we used one-way ANOVA followed by Bonferroni’s post hoc test. In experi-
ments in which data differences between two groups were assessed, results
were analyzed using the unpaired t test.
RESULTS
Adenoviral overexpression of IL-6 elevates plasma
IL-6 concentrations and reduces adipose tissue. To
explore the role of IL-6 in b-cell function, we prepared
recombinant adenovirus containing mouse IL-6 cDNA and
injected 3 3 10
7 PFU IL-6 adenovirus intravenously into
C57BL/6N mice (IL-6 mice). Mice administered adenovirus
containing the LacZ gene were used as controls (LacZ-
mice). Immunoblotting of hepatic lysates on day 5 after
adenoviral administration conﬁrmed overproduction of IL-6
in the livers of IL-6 mice (Fig. 1A). As reported previously
(12,17,19), systemic infusion of recombinant adenovirus
resulted in selective transgene expression in the liver with
no detectable expression in other tissues (data not shown).
Thus hepatic overexpression of IL-6 was achieved and IL-6
produced in the liver was secreted into the systemic cir-
culation, resulting in signiﬁcant plasma IL-6 elevation, with
concentrations peaking at 1,407 6 3 6 8p g / m Lo nd a y5a f t e r
adenoviral administration (Fig. 1B). These plasma IL-6
concentrations in IL-6 mice were within the range of those
observed in ob/ob and db/db mice, murine models of severe
obesity (20–22). In contrast, plasma concentrations of TNF-a,
another proinﬂammatory cytokine related to obesity, were
similar in these two groups of mice (Fig. 1C). Plasma
glucagon concentrations were signiﬁcantly higher in IL-6
mice (Fig. 1D) than in control mice, which is consistent
with the previous report that IL-6 KO mice exhibited low
glucagon levels (3). Body weights tended to be reduced in
IL-6 mice as compared with those in LacZ-mice and mice
without adenoviral administration, although the differences
did not reach statistical signiﬁcance (Fig. 1E). No hepatic
architecture changes or cell inﬁltrations were revealed by
histological analyses in IL-6 mice (Fig. 1F). Circulating
concentrations of transaminases (Fig. 1G), liver weights
(Fig. 1H), and hepatic triglyceride content (Fig. 1I)w e r e
similar in IL-6 and LacZ-mice.
Consistent with the ﬁndings in mice with IL-6 over-
expression in muscle (10), IL-6 mice exhibited reductions
in fat masses, i.e., epididymal fat weights (Fig. 2A) and the
size of adipocytes, compared with LacZ-mice (Fig. 2B).
Daily food intakes of IL-6 mice were decreased (Fig. 2C),
and resting oxygen consumptions were signiﬁcantly in-
creased in IL-6 mice (Fig. 2D). The resultant negative en-
ergy balance may explain fat mass reductions. One-shot
intracerebroventriclar administration of IL-6 reportedly
increased energy expenditure (23) and decreased food
intake (24). Because IL-6 reportedly passes across the
blood-brain barrier (25), the chronic hyper-IL-6-emia ob-
served in IL-6 mice might affect the central nervous system.
Consistent with the fat mass reduction, circulating leptin
concentrations were decre a s e di nI L - 6m i c e( F i g .2 E). How-
ever, circulating adiponectin concentrations were decreased
in IL-6 mice (Fig. 2F). This result may be explained by the
reported ﬁnding that IL-6 has an inhibitory effect on adi-
ponectin production by adipocytes (10,26,27).
IL-6 mice exhibit enhancement of GSIS. Next, to ex-
plore the impact of circulating IL-6 elevation on glucose
metabolism, intraperitoneal GTT were performed on day 5
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improvement of glucose tolerance compared with LacZ-
mice (Fig. 3A). Plasma insulin and C-peptide concentrations
after glucose loading were remarkably higher in IL-6 mice
than in LacZ-mice, whereas fasting insulin and C-peptide
levels were similar in these two groups (Fig. 3B and C).
In contrast, ITT revealed no signiﬁcant difference in insulin
sensitivity between these two groups of mice (Fig. 3D).
These ﬁndings indicate that improvement of glucose
tolerance, especially after glucose loading, in IL-6 mice is
attributable to enhancement of GSIS. On the other hand,
pancreatic islet sizes were apparently similar in LacZ- and
IL-6 mice (Fig. 3E). Quantitatively, b-cell areas (Fig. 3F)
and pancreatic insulin content (Fig. 3G) did not differ be-
tween these groups of mice.
Fasting blood glucose levels were also lowered in IL-6
mice, and this effect persisted for 14 days after adenoviral
administration (Fig. 3H). This result is compatible with the
FIG. 1. Adenoviral overexpression of IL-6 raises plasma IL-6 concentrations. Eight-week-old C57Bl/6N male mice were administered adenovirus
containing the LacZ or the IL-6 gene. A: Immunoblotting of hepatic lysates with anti-IL-6 antibody on day 5 after adenoviral administration. B:
Plasma IL-6 concentrations were measured in LacZ- (open circles; n = 5) and IL-6 (closed circles; n = 7) mice through day 20 after adenoviral ad-
ministration. C: Plasma TNF-a concentrations were measured in LacZ- (open bar; n = 5) and IL-6 (closed bar; n = 7) mice on day 5 after adenoviral
administration. D: Fasting plasma glucagon levels were measured in LacZ- (open bar; n = 4) and IL-6 (closed bar; n = 4) mice on day 5 after adenoviral
administration. E: Body weights of control (not administered adenovirus) (shaded bar; n = 5), LacZ- (open bar; n = 5), and IL-6 (closed bar; n =7 )
mice on day 7 after adenoviral administration. F: Histological ﬁndings of the liver with hematoxylin and eosin staining on day 5 after adenoviral
administration. Scale bars indicate 100 mm. G–I: Plasma aspartic aminotransferase (AST) and alanine aminotransferase (ALT) levels (G), liver
weights (H), and hepatic triglyceride content (I) were measured in LacZ- (open bars; n = 5) and IL-6 (closed bars; n = 7) mice on day 5 after ad-
enoviral administration. *P < 0.05; **P < 0.01 vs. LacZ-mice assessed by unpaired t test in B–D, G–I, and by one-way ANOVA followed by Bonferroni’s
post hoc test in E. Data are presented as means 6 SE. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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duction (19). IL-6 reportedly activates the signal transducer
and activator of transcription-3 (STAT-3) signaling, leading
to downregulation of gluconeogenic genes in hepatocytes
(28). Consistent with this notion, expressions of gluconeo-
genic genes, such as phosphoenolpyruvate carboxykinase
and glucose-6-phosphatase, were signiﬁcantly decreased in
the livers of IL-6 mice (Fig. 3I). In addition, pyruvate tol-
erance tests revealed that blood glucose levels after pyru-
vate loading were signiﬁcantly lower in IL-6 mice than in
LacZ-mice (Fig. 3J). These ﬁndings together indicate that
hepatic glucose production was suppressed in IL-6 mice,
supporting the previously reported observation that hepatic
gluconeogenic gene expressions and fasting blood glucose
levels were suppressed in mice with muscle-speciﬁcI L - 6
overexpression (10).
A lipolytic effect of IL-6 was previously reported (29),
and lipolysis raises circulating FFA concentrations. Be-
cause FFAs are known to be potent insulinotropic factors
(30), we evaluated plasma FFA concentrations. However,
plasma FFA concentrations of IL-6 mice on day 5 after
adenoviral administration did not differ signiﬁcantly from
those of LacZ-mice (Fig. 3K). Thus FFAs are unlikely to be
involved in the enhancement of GSIS in IL-6 mice.
IL-6 enhances GSIS from both isolated pancreatic
islets and MIN-6 cells. These in vivo ﬁndings prompted
us to investigate the direct effects of IL-6 on pancreatic
b-cells. Therefore, we isolated pancreatic islets from
C57BL/6N mice, and the isolated islets were incubated in
medium containing 1,200 pg/mL recombinant IL-6 for 48 h,
followed by examination of GSIS. Note that the IL-6 con-
centrations used in these in vitro experiments were similar
to the plasma IL-6 concentrations in IL-6 mice on day 5
after adenoviral administration (Fig. 1B). At this time
point, GSIS enhancements were observed in IL-6 mice
(Fig. 3B). As shown in Fig. 4A, IL-6 pretreatment markedly
enhanced insulin secretion in response to 16.7 mmol/L
glucose, whereas enhancement of insulin secretion was
not statistically signiﬁcant at 1.67 mmol/L glucose. Pre-
treatment with IL-6 at a lower concentration, 600 pg/mL,
FIG. 2. Adenoviral overexpression of IL-6 reduces adipose tissue. A: Epididymal fat weights in LacZ- (open bar; n = 5) and IL-6 (closed bar; n =7 )
mice were measured on day 5 after adenoviral administration. B: Histological ﬁndings of the epididymal fat tissue with hematoxylin and eosin
staining on day 5 after adenoviral administration. Scale bars indicate 100 mm. C: Mean daily food intakes for 5 days were calculated in LacZ- (open
bar; n = 5) and IL-6 (closed bar; n = 7) mice. D–F: Resting oxygen consumption (n = 3 per group) (D) and plasma levels of leptin (E) and
adiponectin (F) were measured in LacZ- (open bars; n = 5) and IL-6 (closed bars; n = 7) mice. *P < 0.05; **P < 0.01 vs. LacZ-mice assessed by
unpaired t test. Data are presented as means 6 SE. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 3. Adenoviral overexpression of IL-6 enhances GSIS. A–C: Blood glucose (A), plasma insulin (B), and plasma C-peptide (C) levels during
glucose tolerance tests performed in LacZ- (open circles; n = 5) and IL-6 (closed circles; n = 7) mice on day 5 after adenoviral administration.
Statistical signiﬁcance was calculated using the unpaired t test. D: Blood glucose levels after intraperitoneal insulin injection in LacZ- (open
circles; n = 5) and IL-6 (closed circles; n = 7) mice on day 7 after adenoviral administration. Data are presented as percentages of the blood glucose
levels immediately before insulin loading. E: Histological ﬁndings of the pancreas with hematoxylin and eosin staining on day 5 after adenoviral
administration. Scale bars indicate 100 mm. F: b-cell areas of LacZ- (open bars; n = 5) and IL-6 (closed bars; n = 7) mice on day 14 after adenoviral
administration. G: Pancreatic insulin contents were determined in LacZ- (open bars; n = 5) and IL-6 (closed bars; n = 7) mice on day 14 after
adenoviral administration. H: Fasting blood glucose levels were measured in LacZ- (open circles; n = 5) and IL-6 (closed circles; n = 7) mice through
day 20 after adenoviral administration. I: Hepatic expressions of PEPCK (left) and glucose-6 (right) of LacZ- (open bars; n = 5) and IL-6 (closed
bars; n = 7) mice were analyzed by RT-PCR. J: Blood glucose levels during pyruvate tolerance tests performed in LacZ- (open circles; n = 5) and IL-6
(closed circles; n = 7) mice on day 5 after adenoviral administration. K: Fasting plasma free fatty acid levels were measured in LacZ- (open bar;
n = 5) and IL-6 (closed bar; n = 7) mice on day 5 after adenoviral administration. *P < 0.05; **P < 0.01 vs. LacZ-mice assessed by unpaired t test.
Data are presented as means 6 SE. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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and then incubated with or without 1,200 or 600 pg/mL recombinant IL-6 for 48 h, followed by examination of insulin secretion for 60 min in KRBB
supplemented with either 1.67 or 16.7 mmol/L glucose (n = 4 per group). **P < 0.01 vs. insulin secretion from islets without IL-6 pretreatment
assessed by one-way ANOVA followed by Bonferroni’s post hoc test. B: MIN-6 cells were incubated with or without 1,200 pg/mL recombinant IL-6 for
the indicated periods, followed by measurement of insulin secretion for 60 min in KRBB supplemented with either 1.67 or 16.7 mmol/L glucose (n =6
per group). **P < 0.01 vs. insulin secretion from MIN-6 cells without IL-6 pretreatment assessed by one-way ANOVA followed by Bonferroni’sp o s t
hoc test. C: MIN-6 cells were incubated with or without 1,200 pg/mL recombinant IL-6 for 24 h; the cells were used for RT-PCR analysis. b-actin
expression levels of MIN-6 cells were quantiﬁed and normalized relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels.
Difference was assessed by unpaired t test. D:N o n t a r g e t i n g( N T )s i R N A( o p e nb a r s ;n = 5) or IL-6R siRNA (closed bar; n = 5) were applied to the
MIN-6 cells. After 48 h incubation, the cells were used for RT-PCR analysis. IL-6R expression levels of MIN-6 cells were quantiﬁed and normalized
relative to b-actin mRNA levels. *P < 0.05 vs. NT siRNA transfected MIN-6 cells assessed by unpaired t test. E: Knockdown of IL-6R inhibited IL-6-
mediated enhancement of GSIS from MIN-6 cells. MIN-6 cells were transfected with NT siRNA or IL-6R siRNA for 24 h and then incubated with or
without concomitant 1,200 pg/mL recombinant IL-6 for 24 h, followed by examination of insulin secretion for 60 min in KRBB supplemented with
either 1.67 or 16.7 mmol/L glucose (n = 5 per group). **P < 0.01 vs. insulin secretion from MIN-6 cells without IL-6 pretreatment assessed by one-way
ANOVA followed by Bonferroni’s post hoc test. Data are presented as means 6 SE.
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although insulin content in isolated islets was not altered by
IL-6 pretreatment (Supplementary Table 2). Thus IL-6 di-
rectly enhances insulin secretion, particularly in response to
a high concentration of glucose.
We further conﬁrmed the direct effect of IL-6 on GSIS
using MIN-6 cells, a murine b-cell line that is widely ac-
cepted as maintaining glucose responsiveness of insulin
secretion in a fashion similar to that in primary pancreatic
b-cells (31). MIN-6 cells were incubated in medium
containing 1,200 pg/mL recombinant IL-6 for several pe-
riods, followed by examinations of GSIS. Although no en-
hancement of insulin secretion was observed after 6-h
incubation with IL-6, signiﬁcant increments in glucose
(16.7 mmol/L)-induced insulin secretion were observed in
MIN-6 cells pretreated with IL-6 for more than 24 h, as
compared with IL-6-untreated MIN-6 cells. However, no
enhancement of insulin secretion was observed at low
glucose (1.67 mmol/L) even after 24 h stimulation with IL-6
(Fig. 4B). Thus these data clearly showed that IL-6 directly
enhances GSIS from pancreatic b-cells. Because a 24-h
IL-6-pretreatment period exerted the GSIS-enhancing
maximal effect, we performed the following experi-
ments using MIN-6 cells pretreated for 24 h with IL-6 (Fig.
4B). Under these conditions, neither insulin content
(Supplementary Table 2) nor b-actin expression (Fig.
4C) was signiﬁcantly altered in MIN-6 cells.
Next, to examine whether the effect of IL-6 on enhanced
GSIS from MIN-6 cells is actually mediated by the IL-6R,
we knocked down IL-6R expression using a speciﬁc
siRNA. The speciﬁc siRNA for the IL-6R signiﬁcantly re-
duced expression of IL-6R mRNA in MIN-6 cells (Fig. 4D).
Suppression of IL-6R expression markedly blunted IL-6-
mediated enhancement of GSIS from MIN-6 cells. These
ﬁndings indicate that the IL-6R is substantially and func-
tionally expressed in MIN-6 cells and that IL-6 exerts its
stimulatory effects on GSIS through the IL-6R (Fig. 4E).
IL-6–induced enhancement of GSIS is abrogated by
PLC pathway inhibitors. Acetylcholine has been shown
to enhance GSIS from b-cells, and this GSIS enhancement
is mediated, at least partially, by the PLC pathway (32). In
addition, IL-6 reportedly activates the PLC pathway in
a few other cell types (33,34). Therefore, we next exam-
ined involvement of the PLC pathway in IL-6–induced en-
hancement of GSIS. Isolated pancreatic islets and MIN-6
cells were pretreated with 2 mmol/L U-73122, a PLC in-
hibitor (35), with or without concomitant 1,200 pg/mL IL-6
for 24 h, followed by measurement of GSIS. As shown in
Fig. 5A and B, IL-6–induced enhancement of GSIS from
both isolated pancreatic islets and MIN-6 cells was almost
completely abolished with U-73122. We then further con-
ﬁrmed involvement of the PLC pathway in IL-6–induced
enhancement of GSIS from MIN-6 cells, using another PLC
inhibitor, neomycin. This compound inhibits PLC activity
by binding to phosphatidylinositol 4,5-bisphosphatase
(PIP2) (35). Again, pretreatment with 1.5 mmol/L neomycin
inhibited IL-6–induced enhancement of GSIS from MIN-6
cells (Fig. 5C). Thus two PLC inhibitors, with different
mechanisms of action, inhibited IL-6–induced enhance-
ment of GSIS, strongly suggesting that the underlying
mechanism is mediated by the PLC pathway.
PLC-b1 is involved in IL-6–induced enhancement of
GSIS. To examine which isoform(s) of PLC is involved
in IL-6–induced enhancement of GSIS, we knocked down
several isoforms of PLC in MIN-6 cells, followed by testing
IL-6–induced GSIS. We selected PLC isoforms reportedly
expressed in pancreatic islets or a b-cell line (32,36,37)
and prepared speciﬁc siRNAs for each isoform. Speciﬁc
siRNAs for PLC-b1, -b2,- b3,- g1,- g2, and -d1 signiﬁcantly
suppressed the expression of each PLC isoform in MIN-6
cells (Supplementary Fig. 1). In addition, knockdown of
PLC-b1 and PLC-g1 was conﬁrmed by immunoblotting (Sup-
plementary Fig. 2). Among them, in PLC-b1-knockdown
MIN-6 cells, IL-6 pretreatment did not enhance GSIS (Fig. 5D).
These results suggest that PLC-b1 is involved in the stimu-
latory effects of IL-6 on GSIS.
IL-6–induced enhancement of GSIS is not abrogated
by a PKA inhibitor. The cyclic AMP (cAMP)-protein ki-
nase A (PKA) pathway, activated by incretins or glucagon,
is also well known to enhance GSIS from pancreatic b-cells.
Therefore, we next examined the possible involvement of
the PKA pathway in IL-6–induced enhancement of GSIS
from MIN-6 cells. MIN-6 cells were pretreated with 1 mmol/L
H-89, a selective PKA inhibitor (38), with or without con-
comitant 1,200 pg/mL IL-6 for 24 h, followed by measure-
ment of GSIS. In contrast with the PLC pathway inhibitors,
H-89 did not inhibit IL-6–induced enhancement of GSIS from
MIN-6 cells (Fig. 6A), suggesting a contribution of the
cAMP-PKA pathway to IL-6–induced enhancement of GSIS
to be unlikely.
IL-6–induced enhancement of GSIS is abrogated by an
IP3 receptor antagonist. The aforementioned results
suggest that the PLC pathway is involved in IL-6-mediated
enhancement of GSIS. We further examined the down-
stream pathway from PLC through GSIS enhancement.
PLC activation reportedly leads to hydrolysis of PIP2 into
diacylglycerol and IP3.I P 3 binds to the IP3 receptor on the
endoplasmic reticulum (ER), resulting in the induction of
Ca
2+ release from the ER. This leads to an elevation of
the cytoplasmic free Ca
2+ concentration and subsequently
increases insulin secretion (39). To examine whether this
mechanism is involved, MIN-6 cells were pretreated with
10 mmol/L Xestospongin C, an IP3 receptor antagonist (40),
with or without concomitant 1,200 pg/mL IL-6 for 24 h,
followed by examination of GSIS. Xestospongin C pre-
treatment decreased insulin content of MIN-6 cells, unlike
pretreatments with IL-6, inhibitors, or siRNAs described
above (Supplementary Table 2) but did not affect insulin
secretion at low (1.67 mM) and high (16.7 mM) concen-
trations of glucose, when expressed as percentage of in-
sulin content (Fig. 6B). In addition, IL-6 pretreatments did
not alter insulin content of Xestospongin C-treated MIN-6
cells (Supplementary Table 2). Under these conditions,
Xestospongin C inhibited IL-6–induced enhancement of
GSIS from MIN-6 cells (Fig. 6B). Collectively, these ﬁnd-
ings indicate that IL-6 directly enhances insulin secretion
in response to glucose stimulation through the PLC-IP3–
dependent pathway.
DISCUSSION
IL-6 exerts its effects through binding to a receptor com-
plex consisting of two transmembrane glycoproteins, the
speciﬁc receptor subunit IL-6R and a 130-kDa signal
transducing protein (gp130). Formation of the hexametric
IL-6/IL-6R/gp130 complex initiates activation of two major
signaling pathways, Janus kinase (JAK)-STAT and the
mitogen-activated protein kinase (1). Recently, expressions
of both IL-6R and gp130 in murine b-cells were reported,
and notably, the expression levels of these molecules
were comparable with those in muscle (3), suggesting sub-
stantial impacts of IL-6 on pancreatic b-cells. However,
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diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 543FIG. 5. IL-6 enhances GSIS through the PLC-dependent pathway. A: Pancreatic islets isolated from 8-week-old C57BL/6N mice were pretreated with
vehicle or 2 mmol/L U-73122 with or without concomitant 1,200 pg/mL IL-6 for 24 h, followed by measurement of insulin secretion for 60 min in
KRBB supplemented with either 1.67 or 16.7 mmol/L glucose (n = 5 per group). **P < 0.01 vs. insulin secretion from isolated islets without IL-6
pretreatment assessed by one-way ANOVA followed by Bonferroni’s post hoc test. B and C: MIN-6 cells were pretreated with vehicle or a phar-
macological inhibitor (2 mmol/L U-73122 [B] 1.5 mmol/L neomycin [C]) with or without concomitant 1,200 pg/mL IL-6 for 24 h, followed by mea-
surement of insulin secretion for 60 min in KRBB supplemented with either 1.67 or 16.7 mmol/L glucose (n = 6 per group). **P < 0.01 vs. insulin
secretion from MIN-6 cells without IL-6 pretreatment assessed by one-way ANOVA followed by Bonferroni’s post hoc test. D: MIN-6 cells were
transfected with NT siRNA or the speciﬁc siRNA for each PLC isoform for 24 h and then incubated with or without concomitant 1,200 pg/mL
recombinant IL-6 for 24 h, followed by examination of insulin secretion for 60 min in KRBB supplemented with 16.7 mmol/L glucose (n =5p e r
group). **P < 0.01 vs. insulin secretion from MIN-6 cells without IL-6 pretreatment assessed by one-way ANOVA followed by Bonferroni’s post hoc
test. Data are presented as means 6 SE.
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been reported. At 1,500 pg/mL, IL-6 increased basal insulin
secretion from murine isolated islets (4), and at 100 pg/mL,
IL-6 increased both basal and glucose-stimulated insulin
secretion from HIT-15 cells, a hamster b-cell line (5). On
the other hand, 500–2,000 pg/mL (6) or 200–2,000 pg/mL
(7) of IL-6 decreased GSIS from rat isolated pancreatic
islets and 400 pg/mL IL-6 decreased GSIS from mouse
isolated pancreatic islets (8). Furthermore, 400,000 pg/mL
IL-6 did not alter insulin secretion from MIN-6 cells (9).
Although the reason is unclear, these inconsistencies
might be due to the different IL-6 concentrations and
preincubation periods as well as sources of pancreatic
b-cells used in the experiments. Therefore, in the current
study, to elucidate the role of obesity-induced hyper-IL-6-
emia in insulin secretion, we focused on IL-6 concen-
trations within the range of those observed in ob/ob and db/
db mice, 150–7,000 pg/mL (20–22) in both in vivo and in
vitro experiments. In addition, a circulating IL-6 level as
high as 3,400 pg/mL was reported in obese human subjects
(41). In the present in vivo study, plasma IL-6 concen-
trations were elevated and remained at 900–1,400 pg/mL
during ﬁrst the 10 days after adenoviral IL-6 expression in
the liver. We used a similar concentration, 1,200 pg/mL, of
IL-6 in our in vitro experiments.
We analyzed IL-6 effects on insulin secretion comparing
three different settings of pancreatic b-cells, i.e., murine in
vivo, isolated pancreatic islets ex vivo, and a pancreatic
b-cell line, MIN-6 cells in vitro. Notably, all experiments
showed IL-6–induced enhancement of GSIS, suggesting
a direct effect of IL-6 on pancreatic b-cells. In addition,
IL-6R knockdown, PLC inhibitors, and an IP3 receptor
antagonist almost completely inhibited the IL-6–induced
enhancement of GSIS. PLC activation reportedly leads to
hydrolysis of PIP2 into diacylglycerol and IP3.I P 3 binds to
the IP3 receptor on the ER, resulting in the induction of
Ca
2+ release from the ER. This raises the cytoplasmic free
Ca
2+ concentration and subsequently enhances insulin
secretion (39). Our ﬁndings indicate that activation of the
PLC-IP3–dependent pathway by IL-6 appears to play a ma-
jor role in GSIS enhancement during hyper-IL-6-emia. Ac-
tivation of the PLC pathway by IL-6 signaling has been
reported in several cell types. For instance, direct associ-
ation of gp130 and PLC-g was shown in a Ewing’s sarcoma
cell line (33). Activation of PLC-g1 by IL-6 was also
reported in a pheochromocytoma cell line (34). On the
other hand, in this study, siRNA experiments revealed
knockdown of PLC-b1, but not other isoforms, signiﬁcantly
to blunt IL-6–induced GSIS. Because the degrees of ex-
pression suppression differed among siRNAs speciﬁc for
each PLC isoform (Supplementary Fig. 1), these results do
not exclude the possibility that other PLC isoforms con-
tribute to IL-6-induced GSIS. However, the data strongly
suggest involvement of PLC-b1 itself in the underlying
mechanism. PLC-b1 is reportedly activated by G protein-
coupled receptors (42). Taken together with the results
that long incubation periods, i.e., 24 h, were required for
the stimulatory effects of IL-6 on GSIS, unknown mecha-
nisms involving transcriptional or posttranscriptional
alterations in certain molecules might mediate between
the IL-6R and G protein-coupled receptor pathways.
Stimulatory effects of IL-6 on GSIS were also suggested
in IL-6-KO mice (3). In HF-fed IL-6-KO mice, GSIS was
impaired without alterations in pancreatic b-cell mass,
resulting in postprandial hyperglycemia. The authors mainly
analyzed the effects of IL-6 on pancreatic a-cell expansion,
since IL-6-KO mice exhibited low glucagon levels with im-
paired pancreatic a-cell expansion (3). In the current study,
plasma glucagon concentrations were signiﬁcantly higher in
IL-6 mice. In addition, interestingly, IL-6 enhanced GSIS
more robustly in vivo and in isolated islets than that in MIN-
6 cells (compare Fig. 3B and 4A with 4B). These ﬁndings
suggest that the effects of IL-6 on glucagon secretion from
pancreatic a-cells may have some impact on insulin secre-
tion from b-cells in both in vivo and ex vivo experiments, in
addition to the direct effects of IL-6 on b-cells.
Is the observed IL-6–mediated enhancement of GSIS in-
volved in physiological or pathological states? Obesity leads
to elevation of circulating IL-6. Circulating IL-6 is reportedly
related to fat mass, and this relationship is also observed in
mildly obese human subjects (43), suggesting that circulat-
ing IL-6 increases in the early phase of obesity. Notably, in
human subjects, early in the development of obesity, GSIS
is enhanced (44), and insulin hypersecretion occurs before
blood glucose elevation (45–47). In mice, IL-6 deﬁciency
reportedly raises postprandial blood glucose levels after HF
diet loading (48) mainly due to impaired GSIS (3). In addi-
tion, in human subjects, circulating IL-6 concentrations
correlate positively with ﬁrst-phase insulin secretion, and
this correlation is independent of insulin resistance (11).
Taken together, these observations suggest that the mech-
anism elucidated in this study might be involved in GSIS
enhancement in the early stage of obesity development. We
recently identiﬁed a neuronal pathway from the liver as
being involved in hyperinsulinemia in obese mice (17). In
this regard, insulin hypersecretion during obesity de-
velopment appears to be mediated by both neuronal and
humoral signals, which are thought to cooperatively regulate
FIG. 6. IL-6–induced enhancement of GSIS is abrogated by an IP3
receptor antagonist but not by a PKA inhibitor. MIN-6 cells were
pretreated with vehicle or a pharmacological inhibitor (1 mmol/L H-89
[A]o r1 0mmol/L Xestospongin C [B]) with or without concomitant
1,200 pg/mL IL-6 for 24 h, followed by measurement of insulin secretion
for 60 min in KRBB supplemented with either 1.67 or 16.7 mmol/L
glucose (n = 6 per group). **P < 0.01 vs. insulin secretion from MIN-6
cells without IL-6 pretreatment assessed by one-way ANOVA followed
by Bonferroni’s post hoc test. Data are presented as means 6 SE.
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tribute to maintaining glucose homeostasis during obesity
development. Interestingly, during septic shock states,
hypoglycemia is commonly observed and this phenome-
non is explained by hyperinsulinemia (50,51). It is well-
known that IL-6 is markedly elevated during septic shock.
Collectively, our ﬁndings suggest that hyper-IL-6-emia is
involved in the development of hyperinsulinemia in states
of both obesity and septic shock.
In conclusion, in vivo, ex vivo, and in vitro experiments
consistently demonstrated that IL-6 enhances GSIS from
pancreatic b-cells and that this enhancement of GSIS is
likely to be mediated by the PLC-IP3–dependent pathway.
Modulating the PLC pathway in pancreatic b-cells is a po-
tential therapeutic strategy for achieving efﬁcient post-
prandial insulin secretion.
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